-
Turning Tumors Against Themselves: In Vivo Reprogramming of Cancer Cells into Dendritic Sentinels(Post)
Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaki
Exhibition at the University of Oxford's BioEscalator(Post)Showcasing Innovation Assay Genie recently took part in an engaging event at Oxford’s BioEscalator, a leading innovation hub supporting scientific progress and entrepreneurship. The day
Non-Small Cell Lung Carcinoma: Understanding, Diagnosing, and Treating NSCLC(Post)Non-Small Cell Lung Carcinoma (NSCLC) is the most common type of lung cancer, representing about 85% of all lung cancer cases. NSCLC includes several subtypes, with distinct biological ch
Tesnatilimab: Unveiling the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About TesnatilimabWhat is Tesnatilimab?Tesnatilimab is an anti-CD47 monoclonal antibody designed to block the "don’t eat me" signal used by cancer cells to evade immune respo
IL-10 signalling and regulation(Post)Explore the complexities of Interleukin-10 (IL-10) signaling and regulation, a crucial aspect in immune response modulation and its dual roles in cancer development and therapy. Key Takeaways:
SITC 2024 - Scientific Programme, Venue & Exhibition(Post)SITC 2024: Meet Assay Genie at the Society for Immunotherapy of Cancer Annual MeetingAssay Genie is delighted to be attending and exhibiting at SITC 2024 in Houston, Texas on Friday the
How to Choose a Secondary Antibody(Post)The selection of a secondary antibody is a critical step in the experimental design of various immunodetection methods, including Western Blot, ELISA, immunohistochemistry (IHC), and immunofluores
Biomarkers & Inflammatory markers of atherosclerosis(Post)As atherosclerosis is a complex inflammatory disease, there are many influential biomarkers that contribute to the disease’s progression as well as biomarkers from atherosclerosis related di
TA Cloning(Page) Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
Governing the Fate of Stem Cells With Transcription Factors(Post)The intricate process of stem cell differentiation and self-renewal is a cornerstone of developmental biology and regenerative medicine. At the heart of this complex regulatory mechanism are trans
Apoptosis Unveiled: Your Complete Guide to Intrinsic & Extrinsic Pathways(Post)Cell Biology · Programmed Cell DeathApoptosis: Your Complete Guide to Intrinsic & Extrinsic PathwaysApoptosis is programmed cell death — the controlled, non-inflammatory removal of damaged or unwanted
Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword(Post)Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword In the intricate world of cancer biology, some of our body's most potent defense mechanisms can paradoxically turn against us. Cell
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars(Post)Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects
Renal Cell Carcinoma: Understanding, Diagnosing, and Treating Kidney Cancer(Post)Renal Cell Carcinoma (RCC) is the most common form of kidney cancer, originating in the lining of the proximal renal tubules. RCC accounts for approximately 90% of all kidney cancers and
KIR Blockade: Empowering NK Cells for Superior Tumor Clearance(Post)Introduction to KIR Blockade in Cancer ImmunotherapyNatural killer (NK) cells are crucial components of the innate immune system, responsible for recognizing and destroying virally infec
Tertiary Lymphoid Structures: The Body's Hidden Arsenals in the Fight Against Cancer(Post)Tertiary Lymphoid Structures: The Body's Hidden Arsenals in the Fight Against Cancer Imagine a battlefield within the body, where the immune system stands as the last line of defense against the rele
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies(Post)1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon
TLR4: Unraveling the Role of Inflammation in Cancer Progression(Post)Introduction to TLR4 and Cancer Toll-like receptor 4 (TLR4) is a key component of the innate immune system, primarily responsible for detecting infections and initiating inflammatory resp
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Cytokine neutralisation network(Page) Mononuclear Phagocytes in Health and Disease(Post)Mononuclear phagocytes, essential in immunity and homeostasis, perform diverse roles from phagocytosis to tissue repair, influencing health and disease. Key Takeaways: Mononuclear p
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik
In Vivo Functional Grade Antibodies(Page) Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
Eldelumab: Unlocking the Potential of Anti-TNFSF14 in Inflammatory Diseases(Post)Quick Facts About EldelumabWhat is Eldelumab?Eldelumab is a monoclonal antibody targeting TNFSF14 (LIGHT), a key regulator in immune system signaling, with potential applications in infl
GeniePlex Featured Publications(Page) Nod-Like Receptor Signaling Pathway: A Keystone in Innate Immunity(Post)The innate immune system, a primary line of defense against pathogens, comprises various cellular and molecular mechanisms. Among these, the Nod-like Receptor (NLR) signaling pathways play a criti
Myeloid reprogramming in the tumour microenvironment(Page) Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution(Post)Spatial Transcriptomics: Mapping the Future of Medicine at Cellular Resolution Imagine being able to create a detailed map of a city, not just showing the streets and buildings, but also revealing th
Inflammasome Activation Pathways: A Comprehensive Overview(Post)Inflammasomes are complex intracellular structures that play a pivotal role in the immune response by detecting pathogenic microorganisms and sterile stressors. Their activation is a critical step
The Rise of Cancer Neuroscience: How Neural Circuits Drive Tumor Progression(Post)For decades, we viewed cancer as a rogue army of cells, a biological glitch driven solely by genetic mutations and metabolic greed. We imagined tumors as isolated fortresses, growing in a vacuum of t
Genieplex Multiplex Citations(Page) TGF-β/SMAD signalling(Page) Ferroptosis: A New Frontier in Cancer Therapy(Post)For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-inducin
Sodium and Potassium Indicators and Ionophores: A Comprehensive Insight(Post)Understanding the dynamics of sodium and potassium ions within biological systems is crucial for deciphering cellular processes and developing therapeutic strategies. Sodium and potassium indicato
Enzyme Activity Assays(Page) Tumor-Associated Macrophages: Double Agents in the Cancer Battlefield(Post)Tumor-Associated Macrophages: Double Agents in the Cancer Battlefield In the intricate theater of the human body, the immune system acts as a vigilant guardian, dispatching cellular soldiers to seek
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
Trained Immunity: Reprogramming Innate Immune Memory for Future Health(Post)What if our first line of immune defense, the innate immune system, could learn from past encounters to fight future battles more effectively? For decades, we believed this was the exclusive domain of
Mesenchymal Stem Cells: Navigating the Frontiers of Regenerative Medicine(Post)Mesenchymal stem cells (MSCs) have emerged as pivotal players in the realm of regenerative medicine due to their unique properties and versatile potential. Originally discovered in the bone marrow
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
Trained Immunity: How Your Innate Immune System Learns and Remembers(Post)For decades, immunologists believed that only adaptive immunity—the sophisticated system of T cells and B cells—could form lasting memories of past infections. The innate immune system, our body's fir
DNA Origami in the Brain: How Nanoscale Structural Folding Governs Neural Development(Post)Imagine a world where we can fold the very fabric of life into microscopic machines, guiding the growth of a single neuron with the precision of a master architect. This isn't science fiction; it is
Cytokine JAK/STAT signalling(Page) Enhancing PD-L1 Stability Through EZH2 Inhibition(Post)Enhancing PD-L1 Stability: The Role of EZH2 InhibitionIn recent years, the role of PD-L1 (Programmed Death-Ligand 1) in cancer immunotherapy has garnered significant attention, particularly regarding
Western Blot Sample Protocol - Mandarin(Page)蛋白质印迹样本方案(Western Blot,中文) | Assay Genie
A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics(Post)A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disease that has long puzzled researchers and clinicians. Howeve
IL-10 신호 및 규제(Page) Optimizing Organoid Culture Conditions: Paving the Way for Revolutionary Advances in Biomedical Research(Post)In the dynamic landscape of biomedical research, organoids have emerged as a groundbreaking tool, offering three-dimensional (3D) models that mimic the complex architecture and functionality of hu
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
Multiplex Assays(Page)GeniePlex Multiplex Assays | Bead-Based Multiplex Immunoassays | Assay Genie
Macrophage Activation: A Keystone in Immune Response and Therapeutic Potential(Post)In the intricate tapestry of the immune system, macrophages play a pivotal role, orchestrating a wide range of biological responses that protect the body against pathogens, remove cellular debris,
Resources(Page) Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
GeniePlex Multiplex Immunoassay FAQ(Page) Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Ivuxolimab: Redefining Cancer Immunotherapy and Research(Post)Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does
Natalizumab: Mechanism, Applications, and Emerging Research in Multiple Sclerosis and Crohn's Disease(Post)Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at
Emapalumab: Unlocking the Potential of Targeting IFN-γ in HLH Treatment(Post)Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary